Key Points
- Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
- Use system-specific risk tools to guide testing and disposition.
- Order high-yield tests first; escalate imaging when indicated.
- Start evidence-based initial therapy and reassess frequently.
Algorithm
- Primary survey and vitals; IV access and monitors.
- Focused history/physical; identify red flags and likely etiologies.
- Order system-appropriate labs and imaging (see Investigations).
- Initiate guideline-based empiric therapy (see Pharmacology).
- Reassess response; arrange consultation and definitive management.
Clinical Synopsis & Reasoning
Asthma exacerbations reflect acute airway inflammation and bronchoconstriction triggered by infection, allergens, or irritants. Assess severity via work of breathing, PEF/FEV₁, and gas exchange; identify risk factors for near‑fatal events (prior intubation, repeated ED visits). Distinguish from COPD, anaphylaxis, or PE when atypical features are present.
Treatment Strategy & Disposition
Administer repeated SABA (± SAMA) nebulizations, systemic corticosteroids early, and controlled oxygen to achieve target saturations. Consider IV magnesium for severe attacks and non‑invasive ventilation in impending fatigue; intubate if refractory with attention to dynamic hyperinflation. Discharge when PEF ≥70% predicted and stable, ensuring inhaled corticosteroid‑containing regimen and action plan; admit for persistent hypoxemia, rising CO₂, or poor response.
Epidemiology / Risk Factors
- Smoking/chronic lung disease; infections or immobility (VTE)
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| CXR | Infection/edema/PTX | Consolidation/effusion/PTX | |
| ABG/VBG | Oxygenation/ventilation | Hypoxemia/hypercapnia | |
| CT chest (indicated) | PE/other | Findings vary |
Response by Peak Flow
| PEF (% predicted) | Disposition |
|---|---|
| ≥70% and improving | Discharge with meds plan |
| 40–69% | Observe/continue therapy; consider admit |
| <40% or drowsy/CO₂ rising | ICU/acute care; consider NIV/intubation |
Pharmacology
| Medication | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Albuterol (neb) | β2-agonist | Minutes | Bronchodilation rescue | Tachycardia tremor |
| Ipratropium (neb) | M3 antagonism | Minutes | Adjunct bronchodilation (moderate-severe) | Dry mouth |
| Magnesium sulfate (IV) | Ca²⁺ antagonism (bronchodilation) | Minutes | Severe exacerbation refractory | Hypotension |
| Systemic corticosteroid | Glucocorticoid receptor | Hours | Reduce airway inflammation | Hyperglycemia, mood changes |
| Epinephrine (IM) | α/β agonist | Minutes | Impending respiratory failure/anaphylaxis overlap | Arrhythmia |
Prognosis / Complications
- Depends on severity/oxygenation; respiratory failure risk
Patient Education / Counseling
- Explain red flags and when to seek emergent care.
- Reinforce medication adherence and follow-up plan.
Notes
Avoid routine antibiotics. Check for triggers (viral illness, allergens). Educate on inhaler technique and action plan.
References
Use the Library, QBank, CCS, and analytics in one study workflow.
You just reviewed Asthma Exacerbation — Adult. MDSteps helps you turn that review into exam-style practice, missed-item flashcards, and a readiness dashboard that shows what to study next.
- 16,000+ USMLE-style questions across Step 1, Step 2, and Step 3
- CCS simulator with timed orders, live vitals, and case feedback
- Depth-on-Demand™ explanations and Anki-exportable flashcards
- Library + QBank + analytics for $27/month or $299 lifetime